Date:	2022/05/16
Your Name:	Aditi Khandelwal
Manuscript Title:	Applying Principles of Patient Blood Management During COVID-19 Pandemic: A Narrative Review
Manuscript Number (if known):	AOB-2021-BTC-04 (AOB-22-1)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None Click the tab key to add additional rows.	
			Time frame: past 36 month	ns .
2	Grants or contracts from any entity (if not indicated in item #1 above).	X	None	
3	Royalties or licenses	X	None	

			Il entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X	None	
6	Payment for expert testimony	X	None	
7	Support for attending meetings and/or travel	X	None	
8	Patents planned, issued or pending	X	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		None Member, AABB Uniform Donor History Taskf	orce

			omments (e.g., if payments were to your institution)		
11	Stock or stock options	None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None			
13	Other financial or non-financial interests	None			
Plea	Please place an "X" next to the following statement to indicate your agreement:				
Х	C I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Dr. Khandelwal is member of AABB Uniform Donor History Taskforce

Date:	5/17/2022
Your Name:	Heather VanderMeulen
Manuscript Title:	Applying Principles of Patient Blood Management During COVID-19
Manuscript Number (if known):	AOB-2021-BTC-04 (AOB-22-1)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

			Il entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X	None Click the tab key to add additional rows.	
			Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	Canadia	None n Blood Services fellowship funding	
3	Royalties or licenses	×	None	

			Ill entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X	None	
6	Payment for expert testimony		None	
7	Support for attending meetings and/or travel		None	
8	Patents planned, issued or pending		None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	×	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X	None	

			l entities with whom you have this thip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	X	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	×	None	
13	Other financial or non-financial interests	X	None	

Please place an "X" next to the following statement to indicate your agreement:

☑ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

May 16, 2022

Date:

Your Name:			Bryan Tordon		
Manuscript Title:			Applying Principles of Patient Blood Management During COVID-19		
Manuscript Number (if known):			AOB-2021-BTC-04 (AOB-22-1)		
content of your manuscript. "Rel affected by the content of the ma			ted" means any relation with for-profit or no	s/interests listed below that are related to the ot-for-profit third parties whose interests may be not to transparency and does not necessarily indicate, it is preferable that you do so.	
ері	· · · · · · · · · · · · · · · · · · ·	nsion, you	· · · · · · · · · · · · · · · · · · ·	example, if your manuscript pertains to the acturers of antihypertensive medication, even if that	
	tem #1 below, report a			ithout time limit. For all other items, the time	
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
	present manuscript (e.g., funding,	Canadian Services v	None Blood Services Funding for transfusion medicine Figure 2	edicine fellowship provided by Canadian Blood Traineeship Award.	
			Time frame: past 36 month	ns	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None		
3	Royalties or licenses		None		

		Il entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			Il entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Disa					
riea			ollowing statement to indicate your agreeme		
X	I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

		ICIVIJE DISCLOSURE FORIVI
Date:		5/17/2022
Yo	ur Name:	Katerina Pavenski
Ma	anuscript Title:	Applying Principles of Patient Blood Management During COVID-19 Pandemic: A Narrative Review
Ma	anuscript Number (if	known): Click or tap here to enter text.
The epitha	ntent of your manusc ected by the content dicate a bias. If you ar e author's relationshi idemiology of hyperte at medication is not m	arency, we ask you to disclose all relationships/activities/interests listed below that are related to the ript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be of the manuscript. Disclosure represents a commitment to transparency and does not necessarily re in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. ps/activities/interests should be defined broadly. For example, if your manuscript pertains to the ension, you should declare all relationships with manufacturers of antihypertensive medication, even if mentioned in the manuscript. call support for the work reported in this manuscript without time limit. For all other items, the time me past 36 months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Circl the tap key to add additional rows
		Time frame: past 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None
3	Royalties or licenses	None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None ■	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Honorarium for attending advisory board on IV iron in PBM	Pfizer, paid to me
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	■ None	
8	Patents planned, issued or pending	None Non	
9	Participation on a Data Safety Monitoring Board or Advisory Board	■ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None Member, National Advisory Committee on Blood and Blood Products (Canada) Chair, PBM sub-group, Clinical Transfusion Working Party, ISBT Vice-Chair, ICTMG	unpaid unpaid unpaid



		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None ■			
13	Other financial or non-financial interests	⊠ None			
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.					

Rannski May 17 2022